☆ 4.8 Article

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

NATURE MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Michael B. Atkins et al.

Summary: Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma. This study aimed to determine the best initial treatment or treatment sequence in this population.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A. Tawbi et al.

Summary: LAG-3 and PD-1 are two distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab and nivolumab has been shown to be safe and effective in previously treated melanoma patients, and this study aimed to evaluate its safety and activity in previously untreated melanoma patients. The results demonstrated that the combination therapy provided a greater benefit in terms of progression-free survival compared to nivolumab alone, without any new safety signals.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Claire F. Friedman et al.

Summary: This study compared the efficacy of different treatment methods in patients with advanced melanoma through a randomized trial. The results showed that both treatments could induce objective responses, with comparable disease control rates. The findings from biomarker analyses provided hypothesis-generating signals for further research.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Medicine, General & Internal

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan et al.

Summary: This phase 3 trial demonstrates that patients with advanced melanoma who received TIL therapy had significantly longer progression-free survival compared to those who received ipilimumab.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson et al.

Summary: This study is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Ines Pires da Silva et al.

Summary: The study indicates that for patients resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 appears to offer higher efficacy compared to ipilimumab monotherapy, with a higher objective response rate, prolonged progression-free survival, longer overall survival, and a similar rate of grade 3-5 toxicity.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Harriet M. Kluger et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

Spencer C. Wei et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

添加到收藏夹

Article Oncology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

M. T. Tetzlaff et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer immunotherapy using checkpoint blockade

Antoni Ribas et al.

SCIENCE (2018)

添加到收藏夹

Review Oncology

Targeted agents and immunotherapies: optimizing outcomes in melanoma

Jason J. Luke et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Spencer C. Wei et al.

CELL (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma et al.

CELL (2017)

添加到收藏夹

Article Oncology

RECIST 1.1-Update and clarification: From the RECIST committee

Lawrence H. Schwartz et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹

Article Medicine, General & Internal

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Antoni Ribas et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

Padmanee Sharma et al.

CELL (2015)

添加到收藏夹

Editorial Material Medicine, General & Internal

Releasing the Brakes on Cancer Immunotherapy

Antoni Ribas

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Review Multidisciplinary Sciences

The future of immune checkpoint therapy

Padmanee Sharma et al.

SCIENCE (2015)

添加到收藏夹

Article Oncology

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

Lidia Robert et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

Janis M. Taube et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Multidisciplinary Sciences

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh et al.

NATURE (2014)

添加到收藏夹

Article Cell Biology

Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients

Edward Cha et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Editorial Material Oncology

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes

Lidia Robert et al.

ONCOIMMUNOLOGY (2014)

添加到收藏夹

Article Oncology

CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans

Rong Rong Huang et al.

CLINICAL CANCER RESEARCH (2011)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging of CTLA4 Blockade-Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab

Antoni Ribas et al.

JOURNAL OF NUCLEAR MEDICINE (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.